KRAS and neoplasm: Consistent with the notion that NO activates RAS, it was found that the pan‐NO synthase inhibitor L‐NAME reduces tumor growth and enhances the beneficial effect of carboplatin‐based chemotherapy in a mouse model of KRAS and TP53 mutation‐positive nonsmall cell lung carcinomas (NSCLC) [55].